The Psychedelic Comeback скачать в хорошем качестве

The Psychedelic Comeback

MindMed (NASDAQ: MNMD) has surged in 2025 as investors revisit the psychedelic medicine sector. But is this the dawn of a biotech breakout, or another speculative mania? In this deep-dive analysis, we explore the company’s groundbreaking LSD-inspired drug development, financial position, and long-term potential. Could MindMed become a multi-billion-dollar mental health biotech, or is it heading for dilution and disappointment? This video is for educational and informational purposes only. It is not financial advice and not medical advice. See full disclaimers below. In this video, we cover: The global mental health crisis and treatment-resistant disorders MindMed’s pipeline: MM-120 (GAD & ADHD), MM-402 (Autism), and early-stage assets LSD-assisted therapy and the science behind MM-120 Institutional backing and market valuation Financials: cash position, burn rate, and dilution risk Key catalysts and the 2025–2026 investment outlook Risk vs. reward for long-term investors This is a data-driven, balanced analysis of MindMed’s real potential in the psychedelic biotech revolution. 📊 Company SnapshotSector: Biotech / Mental HealthMarket Cap: ~$500MHeadquarters: New York, NYPipeline: Psychedelic-inspired mental health therapeuticsLead Candidate: MM-120 (LSD D-tartrate)Stage: Phase 2 → Phase 3 transition ⚠️ DisclaimerThis video is for educational and informational purposes only. It is not financial advice and not medical advice. Nothing herein should be interpreted as a recommendation to buy or sell any security, nor as endorsement of any medical treatment or controlled substance. Psychedelic compounds should only be used legally within approved clinical settings and under qualified medical supervision. Biotechnology investments carry significant risk, including the risk of total loss. Always do your own research and consult with licensed financial and medical professionals before making decisions. 🎬 Image Attributions Terence McKenna: Jon Hanna. No changes made. Licence: CC BY-SA 3.0 Timothy Leary: John Malmin, Los Angeles Times. Licence: CC BY 4.0 Albert Hofmann: Philip H. Bailey. Licence: CC BY-SA 2.5 #mindmed #mnmd #psychedelics #biotechinvesting #drugdevelopment #clinicaltrials #mm120 #lsdtherapy #nasdaq #stocks #AlphaZen #mentalhealth #fda #biotechstocks #psychedelicstocks #investing #biotech